NT-proBNP is a biomarker that can be measured during a blood test to evaluate possible underlying heart failure. NT-proBNP increases with increased pressure in the heart. NT-proBNP is therefore useful in the diagnosis of heart failure as well as in assessing the prognosis of chronic heart failure.
Stretching of the myocytes in the left ventricular wall due to volume or pressure overload stimulates the production of the inactive protein or prohormone pro-BNP. In the circulation, pro-BNP is cleaved into the inactive N-terminal pro-BNP (NT-proBNP) and the biologically active BNP (Brain Natriuretic Peptide). BNP is one of the natriuretic peptides and ensures increased natriuresis (excretion of sodium through the urine) and vasodilation (reduction in blood pressure), which are beneficial effects in patients with heart failure, because this system of natriuretic peptides tries to reduce the pressure in the heart and thus helps to prevent further overload of the pumping function of the heart.
In heart failure there is an increased concentration of NT-proBNP and BNP in the blood.
BNP and NT-proBNP can be determined in the blood.
NT-proBNP is usually used in practice because it has a longer half-life. In addition, NT-proBNP decreases due to the beneficial effects of therapy with an ARNI, while BNP increases due to its mechanism of action. In patients treated with an ARNI, BNP is no longer useful as a biomarker , but NT-proBNP is.
However, the determination of NT-proBNP and BNP has still not been reimbursed in Belgium in 2024 (cost: 25 to 40 euros per test at the expense of the patient). The determination must therefore be made carefully and preferably in consultation with the patient in order to avoid unnecessary or unwanted costs for the patient.
In unexplained dyspnea on exertion in patients without known heart failure, without clear clinical signs of heart failure (diagnostic uncertainty). For the sake of completeness, it is best to also determine the D-dimers to exclude pulmonary embolism.
If heart failure is suspected on clinical grounds, NT-proBNP can therefore be used as an aid to rule out the disease. In primary care, the NT-proBNP determination has a high negative predictive value (88-98%). This means that a negative result indicates with great certainty that there is no heart failure. However, the positive predictive value is much lower (32-70%). An increased value can therefore also be the result of another cause (see below).
An increased NT-proBNP concentration can be used as an indication for additional echocardiographic examination or for referral to the cardiologist. The higher the increase in NT-proBNP, the sooner cardiological review should be performed.
Research has defined certain cut-off concentrations for NT-proBNP. Below these threshold values, heart failure is almost certainly excluded.
NT-proBNP also increases with age. In a chronic situation, the limit for a normal value is higher in patients ≥ 75 years of age to prevent overdiagnosis and unnecessary further examinations. In patients with unexplained dyspnea on exertion, these are the cut-off values:
The cut-off values are also higher in acute heart failure than in chronic heart failure. In acute dyspnea, global heart failure is almost certainly excluded with an NT-proBNP < 300 pg/ml. As age increases, the limit value for the probability of acute heart failure also increases in the acute setting, as shown in this table.
In patients with known heart failure, the concentration of NT-proBNP has a prognostic value. The higher the value, the worse the prognosis. However, the serial determination of NT-proBNP is not yet recommended, partly because this test is still not reimbursed in Belgium. If indicated by the cardiologist, this test can sometimes be useful, for example in poorly symptomatic patients in NYHA class II. These patients can sometimes still have a significantly elevated NT-proBNP despite only limited symptoms, which is an additional argument for further increasing the therapy.
Sometimes certain heart failure patients with persistent dyspnea symptoms may still have a low NT-proBNP, which then indicates that other factors still contribute to the dyspnea and not heart failure.
A correct interpretation of the NT-proBNP can sometimes be difficult. The NT-proBNP is not specific for heart failure and can also be increased or decreased by other factors. The interpretation of the value of the NT-pro-GNP must therefore be correct and nuanced.
The following factors influence the concentration of NT-proBNP in the blood: